Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
MYOS's Cash to Debt is ranked higher than
95% of the 1152 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.37 vs. MYOS: No Debt )
MYOS' s 10-Year Cash to Debt Range
Min: 0.13   Max: No Debt
Current: No Debt

Equity to Asset 0.91
MYOS's Equity to Asset is ranked higher than
97% of the 1034 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. MYOS: 0.91 )
MYOS' s 10-Year Equity to Asset Range
Min: 0.17   Max: 0.95
Current: 0.91

0.17
0.95
F-Score: 4
Z-Score: 7.26
M-Score: -1.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -155.70
MYOS's Operating margin (%) is ranked lower than
53% of the 1102 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.84 vs. MYOS: -155.70 )
MYOS' s 10-Year Operating margin (%) Range
Min: -4642.42   Max: -128.6
Current: -155.7

-4642.42
-128.6
Net-margin (%) -133.38
MYOS's Net-margin (%) is ranked lower than
53% of the 1102 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.10 vs. MYOS: -133.38 )
MYOS' s 10-Year Net-margin (%) Range
Min: -5653.54   Max: -128.48
Current: -133.38

-5653.54
-128.48
ROE (%) -72.49
MYOS's ROE (%) is ranked lower than
53% of the 1129 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.93 vs. MYOS: -72.49 )
MYOS' s 10-Year ROE (%) Range
Min: -2351.68   Max: -88.51
Current: -72.49

-2351.68
-88.51
ROA (%) -63.75
MYOS's ROA (%) is ranked lower than
55% of the 1161 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.32 vs. MYOS: -63.75 )
MYOS' s 10-Year ROA (%) Range
Min: -398.22   Max: -45
Current: -63.75

-398.22
-45
ROC (Joel Greenblatt) (%) -213.16
MYOS's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 1156 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.14 vs. MYOS: -213.16 )
MYOS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -306400   Max: -252
Current: -213.16

-306400
-252
Revenue Growth (3Y)(%) 144.50
MYOS's Revenue Growth (3Y)(%) is ranked higher than
100% of the 932 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. MYOS: 144.50 )
MYOS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 144.5
Current: 144.5

0
144.5
EBITDA Growth (3Y)(%) -26.80
MYOS's EBITDA Growth (3Y)(%) is ranked higher than
54% of the 839 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. MYOS: -26.80 )
MYOS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -26.8   Max: 357.1
Current: -26.8

-26.8
357.1
EPS Growth (3Y)(%) -30.00
MYOS's EPS Growth (3Y)(%) is ranked higher than
56% of the 811 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. MYOS: -30.00 )
MYOS' s 10-Year EPS Growth (3Y)(%) Range
Min: -30   Max: 358.7
Current: -30

-30
358.7
» MYOS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with MYOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.00
MYOS's P/B is ranked higher than
82% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.13 vs. MYOS: 2.00 )
MYOS' s 10-Year P/B Range
Min: 1.98   Max: 16.26
Current: 2

1.98
16.26
P/S 3.60
MYOS's P/S is ranked higher than
63% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. MYOS: 3.60 )
MYOS' s 10-Year P/S Range
Min: 3.61   Max: 500
Current: 3.6

3.61
500
EV-to-EBIT -2.07
MYOS's EV-to-EBIT is ranked lower than
55% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.18 vs. MYOS: -2.07 )
MYOS' s 10-Year EV-to-EBIT Range
Min: -11.4   Max: -1.1
Current: -2.07

-11.4
-1.1
Current Ratio 8.90
MYOS's Current Ratio is ranked higher than
94% of the 1100 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.13 vs. MYOS: 8.90 )
MYOS' s 10-Year Current Ratio Range
Min: 0.54   Max: 21.45
Current: 8.9

0.54
21.45
Quick Ratio 5.74
MYOS's Quick Ratio is ranked higher than
91% of the 1100 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. MYOS: 5.74 )
MYOS' s 10-Year Quick Ratio Range
Min: 0.18   Max: 20.41
Current: 5.74

0.18
20.41
Days Inventory 305.31
MYOS's Days Inventory is ranked higher than
56% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.81 vs. MYOS: 305.31 )
MYOS' s 10-Year Days Inventory Range
Min: 43.32   Max: 1919.9
Current: 305.31

43.32
1919.9
Days Sales Outstanding 107.22
MYOS's Days Sales Outstanding is ranked higher than
67% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 89.68 vs. MYOS: 107.22 )
MYOS' s 10-Year Days Sales Outstanding Range
Min: 66.36   Max: 107.22
Current: 107.22

66.36
107.22

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.83
MYOS's Price/Net Cash is ranked higher than
88% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MYOS: 14.83 )
MYOS' s 10-Year Price/Net Cash Range
Min: 6.63   Max: 23.79
Current: 14.83

6.63
23.79
Price/Net Current Asset Value 3.01
MYOS's Price/Net Current Asset Value is ranked higher than
93% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MYOS: 3.01 )
MYOS' s 10-Year Price/Net Current Asset Value Range
Min: 4.83   Max: 17.44
Current: 3.01

4.83
17.44
Price/Tangible Book 2.81
MYOS's Price/Tangible Book is ranked higher than
79% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. MYOS: 2.81 )
MYOS' s 10-Year Price/Tangible Book Range
Min: 4.87   Max: 80.17
Current: 2.81

4.87
80.17
Price/Median PS Value 0.34
MYOS's Price/Median PS Value is ranked higher than
99% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. MYOS: 0.34 )
MYOS' s 10-Year Price/Median PS Value Range
Min: 0.47   Max: 7
Current: 0.34

0.47
7
Earnings Yield (Greenblatt) -47.90
MYOS's Earnings Yield (Greenblatt) is ranked lower than
63% of the 1148 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. MYOS: -47.90 )
MYOS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -43.8   Max: 74436.8
Current: -47.9

-43.8
74436.8

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
MYOS Corp was incorporated in the State of Nevada on April 11, 2007. The Company is engaged in the discovery, development and commercialization of nutritional supplements, functional foods, therapeutic products and other technologies aimed at maintaining or improving the health and performance of muscle tissue. In February 2011, the Company acquired its platform dietary supplement product called MYO-T12. Its trademark includes FORTETROPIN. Its competition includes numerous nutritional supplement companies that are fragmented in terms of geographic market coverage, distribution channels and product categories.
» More Articles for MYOS

Headlines

Articles On GuruFocus.com
MYOS Corporation's Preclinical Study of Fortetropin's(TM) Mechanism of Action Demonstrate Regulatory Jan 22 2015 
MYOS Corporation to Present at the Eighth Annual OneMedForum Conference on January 13, 2015 Jan 07 2015 
MYOS Corporation Announces $1.81 Million Registered Direct Offering Nov 18 2014 
MYOS Corporation to Announce Third Quarter 2014 Financial Results and Host Conference Call on Novemb Nov 11 2014 
MYOS Corporation Announces Positive Safety Data Demonstrating Fortetropin's(TM) Lack of Adverse Effe Nov 04 2014 
MYOS Corporation Announces Statistically Significant Top-Line Clinical Data Demonstrating Fortetropi Oct 30 2014 
MYOS Corporation to Present Positive Clinical Data at 55th Annual Conference of the American College Oct 15 2014 

More From Other Websites
Nasdaq stocks posting largest percentage increases Apr 24 2015
MYOS CORP Financials Apr 02 2015
MYOS Corporation Announces the Re Muscle Health(TM) Series Powered by Fortetropin(R) Mar 30 2015
MYOS Corporation Announces the Re Muscle Health(TM) Series Powered by Fortetropin(R) Mar 30 2015
MYOS CORP Files SEC form 10-K, Annual Report Mar 27 2015
MYOS Corporation to Host Conference Call to Discuss Quarterly Update and Management Highlights Mar 27 2015
MYOS Corporation to Host Conference Call to Discuss Quarterly Update and Management Highlights Mar 27 2015
iHeart Radio's "HealthTech Talk" Show to Feature MYOS Corporation's Ingredient Fortetropin(TM) in... Mar 06 2015
iHeart Radio's "HealthTech Talk" Show to Feature MYOS Corporation's Ingredient Fortetropin(TM) in... Mar 06 2015
MYOS Corporation to Present Mechanism of Action Data at the Experimental Biology Conference Feb 23 2015
MYOS Corporation to Present Mechanism of Action Data at the Experimental Biology Conference Feb 23 2015
Chairman Dr. Robert Hariri of MYOS Corporation to Be Interviewed Live on Clear Channel's "The... Feb 12 2015
MYOS Corporation Research Selected to Be Presented at International Conference on Molecular and... Feb 11 2015
MYOS Corporation's Preclinical Study of Fortetropin's(TM) Mechanism of Action Demonstrate Regulatory... Jan 22 2015
MYOS Corporation's Preclinical Study of Fortetropin's(TM) Mechanism of Action Demonstrate Regulatory... Jan 22 2015
MYOS Corporation to Present at the Eighth Annual OneMedForum Conference on January 13, 2015 Jan 07 2015
MYOS Corporation to Present at the Eighth Annual OneMedForum Conference on January 13, 2015 Jan 07 2015
MYOS CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,... Dec 23 2014
MYOS CORP Files SEC form 8-K, Other Events Dec 01 2014
MYOS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure,... Nov 19 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK